Background: Bupropion was the first alternative to nicotine replacement therapy in the pharmacological treatment for smoking cessation. Its safety profile has been monitored in France via spontaneous reporting.
Objective: To describe all serious adverse reactions (SARs) reported in France since the marketing authorization for bupropion in September 2001, and to analyse risk factors for these SARs.
Design: We collected all spontaneous reports of adverse reactions to bupropion received by all French Regional Pharmacovigilance Centres and by GlaxoSmith-Kline, the manufacturer of bupropion, during the first 3 years of marketing of this agent. We identified the characteristics of the population to whom bupropion was prescribed from the Thales database, which contains information obtained from a representative sample of general practitioners in France. We then compared the population with SARs with the population prescribed the drug (exposed population) to identify possible risk factors such as sex, age and daily dose for the most frequent SARs.
Results: Bupropion was prescribed to 698 000 patients during the first 3 years of marketing in France. In these patients, 1682 cases of adverse reactions were reported; 28% of these involved SARs, mainly cutaneous or allergic reactions (31.2%), including angioedema and serum sickness-like reactions. Serious neurological reactions were frequent (22.5%), mostly comprising seizures; however, questioning revealed that almost half of these patients had a history of seizures or other risk factors. Of the serious neuropsychiatric adverse events reported (17.3%), suicide attempts/suicides were a cause for concern, although risk factors (history of depression, suicide attempts, etc.) were described for 66% of patients experiencing these events. Patients reporting angioedema and serum sickness-like reactions, and those involved in suicide attempts/suicides, were significantly younger than the exposed population. A dose-dependent effect was also apparent for angioedema and for seizures. Cardiovascular SARs, such as ischaemic heart disease (10.1%) or sudden death (2.3%), were very often associated with preexisting coronary artery disease induced by smoking. All these SARs occurred within a median of 12–14 days after drug initiation.
Conclusion: To ensure safer use of bupropion, health professionals must respect the strict contraindications and warnings about use of this drug in patients with a history of seizures. Seizures, angioedema and serum sickness-like reactions were the most frequently reported SARs to bupropion treatment in our study. Moreover, younger people appeared to be more at risk for cutaneous SARs generally, and younger women for angioedema in particular, perhaps because of weight-related differences in pharmacokinetics. A dose-dependent effect for angioedema and the results of skin tests were suggestive of a histamine liberation mechanism. Our analysis showed that taking more notice of the contraindications to use of bupropion could have prevented half the seizures reported to the database. The sex and age characteristics of patients with ischaemic heart disease and suicide attempts in the study population were similar to those of the French population as a whole. Whether bupropion is associated with an increase in these potential adverse effects of therapy can be determined only by epidemiological studies that take into account specific risk factors in the smoking population. Finally, the median time to onset of the SARs identified in this study suggests that prescribers should monitor patients exposed to bupropion more carefully during the first 2 weeks of treatment.
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
No sources of funding were used to assist in the preparation of this study. The authors would like to thank all members of the network of French Regional Centres of Pharmacovigilance and AFSSAPS (Health Products French Safety Agency). The authors would also like to thank Maryse Dudu for her help in administrative organization and Dr B. Daury from GlaxoSmithKline. The authors have no conflicts of interest that are directly relevant to the content of this study.
Aronson JK, editor. Meyler's side effects of drugs. 15th ed. Oxford: Elsevier, 2006Google Scholar
Rush CR, Kollins SH, Pazzaglia PJ. Discriminative-stimulus and participant-rated effects of methylphenidate, bupropion, and triazolam in d-Amphetamine-trained humans. Exp Clin Psychopharmacol 1998 Feb; 6(1): 32–44PubMedCrossRefGoogle Scholar
Ascher JA, Cole JO, Colin JN, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995; 56: 395–401PubMedGoogle Scholar
Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997; 337: 1195–202PubMedCrossRefGoogle Scholar
Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340: 685–91PubMedCrossRefGoogle Scholar
Tashkin DP, Kanner R, Bailey W, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 2001; 357: 1571–5PubMedCrossRefGoogle Scholar
Aubin HJ. Tolerability and safety of sustained-release bupropion in the management of smoking cessation. Drugs 2002; 62 Suppl. 2: 45–52PubMedCrossRefGoogle Scholar
Johnston JA, Lineberry CG, Ascher JA, et al. A 102-center prospective study of seizure in association with bupropion. J Clin Psychiatry 1991; 52(11): 450–6PubMedGoogle Scholar
Boshier A, Wilton LV, Shakir S. Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000. Eur J Clin Pharmacol 2003; 59: 767–73PubMedCrossRefGoogle Scholar
Fagerstrom K. The epidemology of smoking: health consequences and benefits of cessation. Drugs 2002; 62 Suppl. 2: 1–9PubMedCrossRefGoogle Scholar
Kennedy D, Goldman S, Lillie R. Spontaneous reporting in the United States. In: Strom BL, editor. Pharmacoepidemiology. 3rd ed. Chichester: John Wiley and Sons, 2000: 151–74Google Scholar
Summary of product characteristics for Zyban (bupropion). GlaxoSmithKline, 9 July 2002Google Scholar
Benson E. Bupropion-induced hypersensitivity reactions. Med J Aust 2001; 174: 650–1PubMedGoogle Scholar
Stewart JJ, Berkel HJ, Parish RC, et al. Single-dose pharmacokinetics of bupropion in adolescents: effects of smoking status and gender. J Clin Pharmacol 2001; 41(7): 770–8PubMedCrossRefGoogle Scholar
Findlay JW, Van Wyck Fleet J, Smith PG, et al. Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects. Eur J Clin Pharmacol 1981; 21(2): 127–35PubMedCrossRefGoogle Scholar
Hsyu PH, Singh A, Giargiari TD, et al. Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J Clin Pharmacol 1997; 37: 737–43PubMedGoogle Scholar
Pisani F, Oteri G, Costa C, et al. Effects of psychotropic drugs on seizure threshold. Drug Saf 2002; 25(2): 91–110PubMedCrossRefGoogle Scholar
Dunner DL, Zisook S, Billow AA, et al. A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. J Clin Psychiatry 1998; 59(7): 366–73PubMedCrossRefGoogle Scholar
Medicines Control Agency. Zyban (bupropion hydrochloride): safety update. 29 Jul 2002 [online]. Available from URL: http://www.mca.gov.uk [Accessed 2002 Jan 20]
Réseau Sentinelles, Unité INSERM 707 [online]. Available from URL: http://Sentiweb.org [Accessed 2005 Mar 5]
Hall SM, Munoz RF, Reus VI, et al. Nicotine negative affect and depression. J Consult Clin Psychol 1993; 61(5): 761–7PubMedCrossRefGoogle Scholar
Glassman AH, Covey LS, Stetner F, et al. Smoking cessation and the course of major depression: a follow-up study. Lancet 2001; 357: 1929–32PubMedCrossRefGoogle Scholar
Breslau N, Schultz LR, Johnson EO, et al. Smoking and the risk of suicidal behaviour. Arch Gen Psychiatry 2005; 62: 328–34PubMedCrossRefGoogle Scholar
Miller M, Hemenway D, Bell NS, et al. Cigarette smoking and suicide: a prospective study of 300,000 male active-duty army soldiers. Am J Epidemiol 2000; 151: 1060–3PubMedCrossRefGoogle Scholar
US Food and Drug Administration. Worsening depression and suicidality in patients being treated with antidepressant medications. Media release: 22 Mar 2004 [online]. Available from URL: http://www.fda.gov [Accessed 2005 Sep 12]
Balit CR, Lynch CN, Isbister GK. Bupropion poisoning: a case series. Med J Aust 2003; 178: 61–3PubMedGoogle Scholar
Tracey JA, Cassidy N, Casey PB, et al. Bupropion (Zyban) toxicity. Ir Med J 2002; 95(1): 23–4PubMedGoogle Scholar
Rohrig TP, Ray NG. Tissue distribution of bupropion in a fatal overdose. J Anal Toxicol 1992; 16(5): 343–5PubMedGoogle Scholar
Holbrook JH. Nicotine addiction. In: Harrison T, Fauci AS. Harrison's principals of internal medicine. 14th ed. New York: McGraw-Hill, Health Professions Division, 1998Google Scholar
Hubbard R, Lewis S, West J, et al. Bupropion and the risk of sudden death: a self-controlled case-series analysis using The Health Improvement Network. Thorax 2005; 60: 848–50PubMedCrossRefGoogle Scholar
Thun MJ, Day-Lally C, Myers DG, et al. Trends in tobacco smoking and mortality from cigarette use in Cancer Prevention Studies I (1959 through 1965) and II (1982 through 1988). In: Changes in cigarette-related disease risks and their implication for prevention and control. Smoking and tobacco control monograph 8. Bethesda (MD): U.S. Department of Health and Human Services, Public Health Service, National Institute of Health, National Cancer Institute, 1997: 305–82Google Scholar
Tonstad S, Farsang C, Klaene G, et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J 2003; 24(10): 946–55PubMedCrossRefGoogle Scholar